Clinical Trial

A Phase II Study of TollB-001 Tablets in Systemic Sclerosis

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this Phase II study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of TollB-001 Tablets in adults aged 18 to 70 years (male or female) with systemic sclerosis (SSc).
Trial Details
NCT Number NCT07745725
Lead Sponsor Toll Biotech Co. Ltd. (Beijing)
Conditions Systemic Sclerosis (SSc)
Enrollment 36 participants
Start Date 2026-08
Primary Completion 2027-10 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-04